SCHEMBL7499287

SCHEMBL7499287

CCOc1ccnc(N)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.64
NOS1 P29475 3/20 0.64
NOS2 P35228 3/20 0.64
TP53 P04637 2/20 0.52
CYP3A4 P08684 2/20 0.52
S1PR1 P21453 2/20 0.50
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
TSHR P16473 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
NPC1 O15118 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
NQO1 P15559 1/20 0.46
DYRK1A Q13627 1/20 0.46
ALDH1A1 P00352 3/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 3/20 0.42
MAPT P10636 1/20 0.42
NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31348007 1.00 NOS3 (0.64) NOS3NOS1NOS2TP53CYP3A4
SCHEMBL15689737 0.84 NOS3 (0.60) NOS3NOS1NOS2TP53MEN1
SCHEMBL4555865 0.83 NCF1 (0.59) NOS3NOS1NOS2S1PR1MEN1
SCHEMBL25595272 0.82 NOS3 (0.58) NOS3NOS1NOS2CYP3A4MEN1
SCHEMBL11612193 0.80 TSHR (0.58) NOS3NOS1NOS2TSHR
SCHEMBL11291157 0.79 NQO1 (0.46) NOS3NOS1NOS2TP53CYP3A4
SCHEMBL13498506 0.79 NOS3 (0.59) NOS3NOS1NOS2S1PR1MEN1
SCHEMBL731492 0.79 NOS3 (0.63) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL29615484 0.79 NOS3 (0.63) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL4607848 0.78 CCR1 (0.61) NOS1NOS2TP53CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630424-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS Third Harmonic Bio, Inc. (US) 2025-10-15 EP disclosed
WO-2025111547-A1 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF RGENTA THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
US-20250042901-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INT (DE) 2025-02-06 US disclosed
US-12139484-B2 Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-11-12 US disclosed
US-20240254119-A1 COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS Calixis Inc. 2024-08-01 US disclosed
WO-2024124002-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS THIRD HARMONIC BIO, INC. (US) 2024-06-13 WO disclosed
EP-3908579-B1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH INC (US) 2023-12-27 EP disclosed
CN-117105936-A Imidazo [1,2-a ] pyridine compound serving as FLT3 inhibitor, and preparation method and application thereof 遵义医科大学 2023-11-24 CN disclosed
US-20230271942-A1 CDK9 INHIBITOR AND USE THEREOF PHARMABLOCK SCIENCES (NANJING), INC. (CN) 2023-08-31 US disclosed
US-20230271942-A1 CDK9 INHIBITOR AND USE THEREOF PHARMABLOCK SCIENCES (NANJING), INC. (CN) 2023-08-31 US disclosed
WO-2015004481-A1 IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) ASTEX THERAPEUTICS LIMITED (GB) 2015-01-15 WO disclosed
CN-102407708-A Ink jet recording medium and image forming method FUJIFILM CORP 2012-04-11 CN disclosed
EP-1171122-A4 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2002-05-29 EP disclosed
EP-1171122-A1 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2002-01-16 EP disclosed
US-6248755-B1 ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES MERCK & CO., INC. 2001-06-19 US disclosed
WO-2000059502-A1 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-10-12 WO disclosed
EP-0356234-B1 New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1994-05-11 EP disclosed
US-5047411-A Antiulcer Agents, H2-Receptor Antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-09-10 US disclosed
EP-0356234-A2 New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-02-28 EP disclosed
US-3965100-A 2,3-Dihydrocyclopenta[d]pyrido[1,2-a]pyrimidin-10(1H)-one and its derivatives E. R. SQUIBB & SONS, INC. (US) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271942-A1 CDK9 INHIBITOR AND USE THEREOF CDK9, CDK19, CDK8 NOS3 4803/4885NOS1 4423/4885NOS2 4744/4885
US-20240254119-A1 COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS KIT, AURKC, PRKCE NOS3 2233/4885NOS1 2638/4885NOS2 2636/4885
US-20250042901-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 RIPK2, RIPK1, RIPK4 NOS3 3538/4885NOS1 3694/4885NOS2 2610/4885
US-12139484-B2 Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease RIPK2, RIPK4, RIPK1 NOS3 1715/4885NOS1 1943/4885NOS2 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.